Cancer

Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.

Cancer

Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

Cancer

Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN

Cognitive functioning in breast cancer survivors: a controlled comparison.

Cancer

Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB

Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.

Cancer

Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D

Fatigue after treatment for early stage breast cancer: a controlled comparison.

Cancer

Jacobsen PB, Donovan KA, Small BJ, Jim HS, Munster PN, Andrykowski MA

Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma.

Cancer

Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB